加载中
NASDAQHealthcareMedical - Diagnostics & Research
最新数据
US$8.25
−US$0.17 · -2.02%
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.
前收盘价
US$8.25
−US$0.17 · -2.02%
盘后
US$8.13
−US$0.12 · -1.45%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.
日内区间
当前US$8.25
52周区间
当前US$8.25
盘中时间采用ET。市场数据可能有所延迟。
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.
日内区间
当前US$8.25
52周区间
当前US$8.25
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 6657.5万 USD | 5564.1万 USD | 5254.8万 USD | 4556.3万 USD | 4829.9万 USD |
| 销货成本 | 2777.6万 USD | 2252.9万 USD | 2309.2万 USD | 2421.4万 USD | 2058.8万 USD |
| 毛利 | 3879.9万 USD | 3311.2万 USD | 2945.6万 USD | 2134.9万 USD | 2771.1万 USD |
| 研究与开发 | 625.4万 USD | 537.5万 USD | 486.5万 USD | 987.6万 USD | 723.7万 USD |
| 销售、一般及管理费用 | 4661.5万 USD | 4137.3万 USD | 4742.8万 USD | 5201.8万 USD | 4454.1万 USD |
| 营业费用 | 5286.9万 USD | 4674.8万 USD | 5229.3万 USD | 6740万 USD | 5177.8万 USD |
| 利息收入 | 28.9万 USD | 76.7万 USD | 151.6万 USD | 83万 USD | 1.6万 USD |
| 利息支出 | 431.8万 USD | 223.4万 USD | 233.5万 USD | 244.8万 USD | 262.5万 USD |
| 折旧和摊销 | 211.8万 USD | 172.4万 USD | 216.8万 USD | 155.7万 USD | 94.8万 USD |
| 营业利润 | −1407万 USD | −1363.6万 USD | −2283.7万 USD | −4605.1万 USD | −2406.7万 USD |
| 净利润 | −1995.1万 USD | −1511.5万 USD | −2368.9万 USD | −4738.7万 USD | −2685.1万 USD |
公司数据更新于 2026年10月13日。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI304.5万0.00%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF139.82万0.00%954亿 USD0.05%US$233.52-0.63%
iShares Micro-Cap ETFIWC37.05万0.03%13.17亿 USD0.60%US$181.66-0.73%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM21万0.18%1.16亿 USD0.73%US$15.8484-0.58%
Invesco NASDAQ Future Gen 200 ETFQQQS13.76万0.60%2275.83万 USD0.20%US$41.414-1.73%
Dimensional - US Core Equity 2 ETFDFAC5.48万0.00%885.96亿 USD0.21%US$45.31-0.04%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMInvesco NASDAQ Future Gen 200 ETFQQQSDimensional - US Core Equity 2 ETFDFACAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
